The Indiana University School of Medicine (IUSM) has a longstanding commitment to the training of medical students in academic medicine and has supported the Student Research Program in Academic Medicine (SRPAM) for 28 years. This application is a competitive renewal of the T35 training grant (Short-Term Training in Biomedical Sciences) awarded to IUSM in 2011 and that greatly contributed to the consolidation and expansion of the program. The purpose of the SPRAM is to provide a structured research environment that engages medical students' interest in biomedical research, creating opportunities for basic and translational research experience, and education in research ethics. The main objective of the program is to serve as a portal to train and recruit physician-scientists. Every year ~40 medical students with strong academic credentials are selected for the SPRAM from a pool of 80-100 applicants, and are paired with highly qualified faculty mentors for 12-week summer research internships with accompanying lecture series focused on research communication, ethics, translational research and career development. The current application seeks support to enroll 32 students/year in the SPRAM (including 8 additional positions) to conduct basic and translational research within the basic and clinical departments and centers at IUSM. The combined support of the T35, Clinical and Translational Sciences Institute, IU Simon Cancer Center and Center of Excellence in Molecular Hematology will allow the enrollment of a higher number of students from the pool of meritorious applicants. The program is designed to: a) increase student awareness to the value of doing biomedical research, challenging them to take on independent projects, and; b) strongly support students interested in careers in academic medicine by providing access to opportunities in the MD/PhD program, and assistance with research fellowship applications to HHMI and NIH. Trainees engage in mentored research experience in areas that reflect the school's strength and international reputation in hematopoiesis, immunity, pulmonary and cardiovascular biology, cancer, diabetes and medical informatics. The strengths of our program are: i) a cadre of >100 selected, successful mentors including physician-scientists, with extramural funding, outstanding training records and solid experience with short-term trainees; ii) an outstanding scientific environment with intense interdisciplinary spirit and access to cutting-edge technologies and excellent resources; iii) a supportive community providing students with opportunities for leadership and mentoring; iv) integration with the medical school curriculum, and; v) an unequivocal commitment from the IUSM leadership. The long term goal of the program is to increase the number of physician-scientists nationally by exposing students in their early years of medical education to hypothesis-driven research focused on the molecular and cellular basis of disease and their potential for clinical translation.

Public Health Relevance

The Student Research Program in Academic Medicine (SRPAM) at the Indiana University School of Medicine, has established a pipeline for students to enter in the MD/PhD or HMI programs and more broadly to encourage them to embrace the career of physician-scientists. The purpose of this T35 renewal program is to continue to sustain this program and to support intensive research training (3 months) for 32 medical students in basic and translational research in the areas of hematopoiesis, immunology and cardiovascular research with highly trained investigators/mentors and in a stimulating environment.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
NRSA Short -Term Research Training (T35)
Project #
2T35HL110854-06
Application #
9208956
Study Section
Special Emphasis Panel (ZHL1-CSR-J (O1))
Program Officer
Meadows, Tawanna
Project Start
2012-03-01
Project End
2022-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
6
Fiscal Year
2017
Total Cost
$238,257
Indirect Cost
$17,649
Name
Indiana University-Purdue University at Indianapolis
Department
Pediatrics
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Pacheco-Costa, Rafael; Davis, Hannah M; Atkinson, Emily G et al. (2018) Reversal of loss of bone mass in old mice treated with mefloquine. Bone 114:22-31
Schroering, Joel R; Kubal, Chandrashekhar A; Fridell, Jonathan A et al. (2018) Impact of Variant Donor Hepatic Arterial Anatomy on Clinical Graft Outcomes in Liver Transplantation. Liver Transpl 24:1481-1484
Delgado-Calle, Jesus; Hancock, Benjamin; Likine, Elive F et al. (2018) MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production. FASEB J 32:2878-2890
Davis, Hannah M; Pacheco-Costa, Rafael; Atkinson, Emily G et al. (2017) Disruption of the Cx43/miR21 pathway leads to osteocyte apoptosis and increased osteoclastogenesis with aging. Aging Cell 16:551-563
Sato, Amy Y; Richardson, Danielle; Cregor, Meloney et al. (2017) Glucocorticoids Induce Bone and Muscle Atrophy by Tissue-Specific Mechanisms Upstream of E3 Ubiquitin Ligases. Endocrinology 158:664-677
Basavarajappa, Halesha D; Sulaiman, Rania S; Qi, Xiaoping et al. (2017) Ferrochelatase is a therapeutic target for ocular neovascularization. EMBO Mol Med 9:786-801
Hauck, Paula M; Wolf, Eric R; Olivos 3rd, David J et al. (2017) Early-Stage Metastasis Requires Mdm2 and Not p53 Gain of Function. Mol Cancer Res 15:1598-1607
Mendonca, Marc S; Turchan, William T; Alpuche, Melanie E et al. (2017) DMAPT inhibits NF-?B activity and increases sensitivity of prostate cancer cells to X-rays in vitro and in tumor xenografts in vivo. Free Radic Biol Med 112:318-326
Meixner, Cory N; Aref, Mohammad W; Gupta, Aryaman et al. (2017) Raloxifene Improves Bone Mechanical Properties in Mice Previously Treated with Zoledronate. Calcif Tissue Int 101:75-81
Doster, Dominique L; Jensen, Amanda R; Khaneki, Sina et al. (2016) Mesenchymal stromal cell therapy for the treatment of intestinal ischemia: Defining the optimal cell isolate for maximum therapeutic benefit. Cytotherapy 18:1457-1470

Showing the most recent 10 out of 31 publications